Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 February 2023 | Story Leonie Bolleurs | Photo Supplied
Rodney Moffett
Prof Rodney Moffett was presented with the Silver Medal Award. At the ceremony were, from the left: Prof Glynis Goodman-Cron, SAAB President, Prof Rodney Moffett, and Prof Sandy-Lynn Steenhuisen.

Prof Rodney Moffett, Honorary Research Fellow in the Department of Plant Sciences at the University of the Free State (UFS) and Top Research Fellow in the Afromontane Research Unit (2018-2019) on the UFS Qwaqwa Campus, was recently awarded a Silver Medal from the South African Association of Botanists (SAAB) at their 48th annual conference that took place in Polokwane.

Prof Sandy-Lynn Steenhuisen, Subject Head and Associate Professor in the Department of Plant Sciences on the UFS Qwaqwa Campus, says, “It was an absolute joy and honour to be able to nominate and present a SAAB Silver Medal to Prof Moffett, who is an iconic figure and friend in our department. I was so happy that he could receive his award in person, with his daughter visiting from the United Kingdom. He inspires my research group so much with his knowledge of plants of the Eastern Free State and through the wealth of specimens he’s contributed to the QWA herbarium.”

The conference with the theme, ‘Plants, Health and Prosperity’, was hosted by the University of Limpopo’s Faculty of Science and Agriculture under the School of Molecular and Life Sciences in the Department of Biodiversity.

Outstanding research contributions 

According to Prof Steenhuisen, Prof Moffett received the Silver Medal Award for his outstanding research that contributed to the advancement of botany and plant sciences in South Africa.

Since his retirement, Prof Moffett has published a number of book chapters, books, reports, and articles on various aspects of fauna and flora. 

He sole-authored eight books and authored/co-authored more than 36 peer-reviewed articles in scientific journals covering mainly the taxonomy of plant genera such as Sarcocaulon, Rhus, and Searsia, and checklists of vascular plants and their medicinal uses for the Qwaqwa and Lesotho regions. 

Around 2006, Prof Moffett pursued his passion to document and describe the ethnobotanical uses of plants used by the Basotho people of Lesotho and South Africa. His books focused, for instance, on the natural history and Sesotho names of the plants used by the Basotho of the Eastern Free State and their ethnobotanical uses, the taxonomic works on the grasses of the Eastern Free State (still the most detailed grass identification guide for the area to date), and the flora and fauna of the Clarens Village Conservancy (a field guide). 

Prof Moffett has also published a scientific bibliography of the Drakensberg, Malotis and adjacent lowlands, which Prof Steenhuisen describes as “a mammoth task and one which he is continually updating and expanding, with another volume in preparation”.

Prof Steenhuisen, who nominated Prof Moffett for the Silver Medal Award, says that as a highly respected naturalist in the Qwaqwa region, he is continually consulted by conservation authorities, researchers, and postgraduate students on the flora of the area. He also regularly presents his research at garden and botanical societies. 

Among the books he has published are Sesotho names of plants and animals and plants used by the Basotho (2010), A biographical dictionary of contributors to the natural history of the Free State and Lesotho (2014), and Meriana ya dimela tsa Basotho – Basotho medicinal plants (2016 and 2020). In 2020, he also published A Scientific Bibliography of the Drakensberg, Maloti and adjacent Lowlands.

Prof Steenhuisen states that Prof Moffett’s books are treasured resources for anyone working in the Maloti-Drakensberg area. 

Best poster presentation

Joining researchers, postgraduate students, and experts from other universities and organisations at the conference, was the Plant Ecology Research Group of Prof Steenhuisen, her postgraduate students, and a postdoctoral fellow involved in invasive species and climate change research. Postgraduates from three other research groups (Plant Biotechnology, Proteomics, and Ethnobotany supervised by Dr Arun Gokul, Dr Rudo Ngara, and Prof Anofi Ashafa) on the Qwaqwa Campus also attended the conference. 

Dr Makoena Moloi, Senior Lecturer in the Department of Plant Sciences on the Bloemfontein Campus, and her postgraduate students researching aspects of plant ecophysiology, were also present at the conference, together with master’s candidate Orateng Sedimo, who is supervised by Dr Lize Joubert, Senior Lecturer in the department. Sedimo presented his honours research and won a prize for presenting the best Honours poster in the category Molecular Systematics. 

Besides being well-represented at the 48th SAAB annual conference and being awarded for its outstanding contributions to botany and plant sciences, academics from the UFS had the opportunity to learn from and network with some of the best scientists in the field. This included A1-rated scientist, Prof Steven Johnson from the University of KwaZulu-Natal, (Prof Steenhuisen’s supervisor for her PhD), and B2-rated Prof Anton Pauw from Stellenbosch University. Prof Johnson and Prof Pauw were respectively awarded a Gold and second Silver Medal from SAAB. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept